Clinical Trials Logo

Parathyroid Dysfunction clinical trials

View clinical trials related to Parathyroid Dysfunction.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06169735 Recruiting - Adenoma Clinical Trials

Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation

Start date: April 11, 2024
Phase: Phase 4
Study type: Interventional

The aim of this study is to determine if fluorescence with or without indocyanine green can facilitate safe and accurate thyroid and parathyroid surgery.

NCT ID: NCT05152927 Recruiting - Adenoma Clinical Trials

Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

Start date: January 10, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to assess whether using PTeye (AiBiomed, Santa Barbara, CA) - a NIRAF detection modality - can improve patient outcomes and reduce healthcare associated costs after parathyroid surgeries. By being able to quickly and definitively locate parathyroid glands while in the operating room, the duration of surgical procedure could be further reduced. In addition, the number of frozen section biopsy and associated costs can be minimized. Furthermore, repeat surgeries as a result of missing a diseased parathyroid gland at the time of the initial parathyroidectomy for hyperparathyroidism could potentially be avoided.

NCT ID: NCT04160637 Recruiting - Clinical trials for Postoperative Complications

Is There Benefit From Early Postoperative PTH Monitoring?

Start date: September 1, 2019
Phase:
Study type: Observational

This study is designed as a prospective non-randomized longitudinal single-center cohort study. It will enroll around 120 patients undergoing total thyroidectomy with data being collected from September 2019 up to December 2019. The hypothesis is that a significant association and cut-off point in PTH levels may be established with regard to postoperativne hypocalcaemia. Primary outcome measures are presence of hypocalcemia on the first and fifth postoperative day. Secondary outcome measures are the need for calcium supplement therapy during the first five postoperative days and amount of medication given. Associations between variables will be assessed using Spearman's rho rank correlation coefficient, the Kruskal-Wallis test for independent samples and a logistic regression model to test statistically significant correlations between PTH and serum calcium values as a primary end point.